Gendicine intratumoral injection combined with radiotherapy for advanced nasopharyngeal carcinoma(phase IV)).
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2017
At a glance
- Drugs Contusugene ladenovec (Primary)
- Indications Nasopharyngeal cancer
- Focus Adverse reactions; Therapeutic Use
- 21 May 2012 Planned end date changed from 1 Apr 2009 to 1 Jan 2017 as reported by Chinese Clinical Trial Register.
- 23 Nov 2011 Status changed from completed to recruiting as reported by Chinese Clinical Trial Register.
- 03 Oct 2009 New trial record